Organon & Co Reports FY Adjusted EPS $3.66, EBITDA Margin 30.7%
Organon & Co posted full-year 2025 revenue of $6.2 billion, down 3% year-over-year, non-GAAP adjusted EPS of $3.66 and adjusted EBITDA of $1.91 billion with a 30.7% margin. It expects 2026 revenue and adjusted EBITDA to remain around $6.2 billion and $1.9 billion and completed the JADA System sale.
1. FY2025 Financial Results
Organon & Co recorded full-year 2025 revenue of $6.2 billion, a 3% year-over-year decline, with non-GAAP adjusted EPS of $3.66. The company generated $1.91 billion in adjusted EBITDA, reflecting a 30.7% margin inclusive of $6 million in IPR&D expenses.
2. 2026 Financial Outlook
The company forecasts 2026 revenue at approximately $6.2 billion and adjusted EBITDA near $1.9 billion, suggesting flat year-over-year performance. Management anticipates maintaining profitability levels while addressing currency and market headwinds.
3. JADA System Divestiture
Earlier in January, Organon completed the sale of its JADA System to Laborie Medical Technologies. The divestiture aligns with the company’s strategy to focus on core therapeutic areas and streamline its portfolio.